Thyroid Gland Medullary Carcinoma clinical trials at UC Health
2 in progress, 1 open to new patients

• Targeted therapy for sarcomas, Wilms tumor, rare tumors that have come back, did not respond to treatment, or are newly diagnosed

  “How well does targeted therapy, (cabozantinib-s-malate) work in treating younger patients with sarcomas and rare tumors?”

  open to eligible people ages 2-30

  This phase II trial studies how well cabozantinib-s-malate works in treating younger patients with sarcomas, Wilms tumor, or other rare tumors that have come back, do not respond to therapy, or are newly diagnosed. Cabozantinib-s-malate may stop the growth of tumor cells by blocking some of the enzymes needed for tumor growth and tumor blood vessel growth.

  at UCSF UC Davis

• Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors

  Sorry, in progress, not accepting new patients

  This phase I trial studies the side effects and best dose of cabozantinib S-malate in treating younger patients with solid tumors that have come back or no longer respond to treatment. Cabozantinib S-malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

  at UCSF

Last updated: February 15, 2019